FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca
SpringWorks Therapeutics’ Gomekli is now FDA approved for treating tumors caused by the rare genetic disorder neurofibromatosis type 1. The approval comes as SpringWorks has emerged as a potential acquisition target. The post FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca appeared first on MedCity News.
SpringWorks Therapeutics’ Gomekli is now FDA approved for treating tumors caused by the rare genetic disorder neurofibromatosis type 1. The approval comes as SpringWorks has emerged as a potential acquisition target.
The post FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca appeared first on MedCity News.
